Lukas Flatz

18PUBLICATIONS
124CO-AUTHORS
Molecular targetsGene and molecular therapyImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 03, 2026
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Oct 13, 2025
Precision medicine in cutaneous melanoma-A comprehensive review.

Markus Reitmajer, Lukas Flatz

|Sep 23, 2025
HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

Leonie Müller-Jensen, Lukas Flatz, Omar Hasan Ali

|Jul 05, 2024
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients.

A Gawaz, I Wolff, L Nanz

|May 02, 2024
Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19.

Nathalie A Lengacher, Julianna J Tomlinson, Ann-Kristin Jochum

Pageof 3

Frequent Collaborators

5 joint publications

Omar Hasan Ali

4 joint publications

Ann-Kristin Jochum

4 joint publications

Wolfram Jochum

2 joint publications

Julianna J Tomlinson